

#22

PATENT
Customer No. 20,462
Attorney Docket No. P32685

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Storm et al.)
Application No.: 09/689,483) Group Art Unit: 1615
Filed: October 12, 2000) Examiner: Rachel Bennett
For: NOVEL METHOD OF TREATMENT)

Commissioner for Patents
Washington, DC 20231

DEC 10 2003

Sir:

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(c)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449 Form. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final action, Quayle action, or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), please charge the fee of \$180.00 as specified by Section 1.17(p) to Deposit Account No. 19-2570.

Applicants resubmit the following U.S. Patents and U.S. applications for the Examiner's specific consideration of possible double patenting rejections. To facilitate the Examiner's review of these documents and avoid the wasteful reproduction of specifications, Applicants submit only the claims issued or pending in these matters, but provide the patent number or serial

number in the chart below. Should the Examiner wish copies of any of these documents, please advise the undersigned at the number below.

US Patent or Application Number	Examiner	GSK Number
USSN 09/544,019 USSN 10/115,700	R. Bennett R. Bennett	P32554 P32554 D1
US Pat. 6,294,199 USSN 09/911,905	R. Bennett R. Bennett	P32555 P32555 D1
USSN 09/971,560	R. Bennett	P32685 C1
USSN 09/974,596	M. Young	P32687
USSN 09/974,572	M. Young	P32688

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form. Should the Examiner conclude that any of these claims form the basis of a double patenting rejection, the Examiner is invited to contact the undersigned to discuss the possible filing of a Terminal Disclaimer.

This submission does not represent that a complete search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 19-2570.

Respectfully submitted,

Dated: March 11, 2003

By: Jean B. Frosis Reg. No. 32,984 for
Dara L. Dinner

Attorney for Applicant
Reg. No. 33,680

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5017
Facsimile (610) 270-5090

RECEIVED

DEC 10 2003

RECEIVED

PLEASE STAMP TO ACKNOWLEDGE RECEIPT OF THE FOLLOWING:

In Re Application of: Storm et al.

Application No.: 09/689,483

Group Art Unit: 1615

Filed: 12 October 2000

Examiner: Rachel M. Bennett

For: NOVEL METHOD FO TREATMENT

1. Second Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97(c) with request to charge deposit account \$180.00 for the filing fee (3 pages);
2. Form PTO 1449 (1 page); and
3. Seven (7) documents.

**HAND DELIVERY TO
EXAMINER R. BENNETT
CRYSTAL MALL 1, 7TH FLOOR**

4012-0331

Dated: March 11, 2003

Docket No.: P32685

Customer No.: 20,462

(Due Date: None)

03/11/03
RECEIVED
03/11/03

*** RX REPORT ***

RECEPTION OK

TX/RX NO	6229
CONNECTION TEL	202 408 4400
CONNECTION ID	
ST. TIME	12/10 15:47
USAGE T	04 '20
PGS.	9
RESULT	OK